Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis

Sherri Huang,Aryanna Jordan, Dakota Jenneman,Michael Shafique, Bjorn Holmstrom

CUREUS JOURNAL OF MEDICAL SCIENCE（2022）

引用 2|浏览1

暂无评分

摘要

Immune checkpoint inhibitors (ICIs) are important novel agents used in advanced non-small cell lung cancer (NSCLC) standard regimens; however, their use increases the risk of immune-related adverse effects (IRAEs). The incidence of IRAE pneumonitis is well documented in ICI use. Corticosteroids continue to be the mainstay of treatment for IRAEs. Here we report one of the first cases of using infliximab to treat durvalumab-associated pneumonitis.

查看译文

关键词

infliximab, drug induced pneumonitis, immune-related adverse event (irae), cancer immunotherapy, non-small cell lung carcinoma (nsclc)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要